Weifang Shengtai Medicine Co., Ltd., a hidden champion in the domestic glucose raw material industry with many years of experience, has always prioritized the iterative upgrading of glucose production processes in its R&D, continuously tackling technological challenges with stringent standards in the high-end pharmaceutical and food raw material market.
In the company's R&D center laboratory, the R&D team is conducting refined experiments focusing on the core aspects of glucose production. Researchers are concentrating on testing the solubility parameters of glucose raw materials, constantly refining the details of the production process. Li Hailiang, director of the company's R&D center, explained, "By optimizing the crystallization temperature and stirring rate, the product's bulk density and crystallization yield have been significantly improved." This technological breakthrough not only further solidifies the product's quality barrier, providing higher purity and more stable high-quality raw materials for downstream food and pharmaceutical fields, but also propels the company's domestic market share of pharmaceutical glucose to nearly 60%, firmly establishing its leading position in the industry. Currently, Shengtai Pharmaceutical's starch and glucose series products cover 30 provinces, autonomous regions, and municipalities in China, and are exported to more than 70 countries and regions worldwide, making it a benchmark enterprise for Chinese glucose raw material exports.
